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Background: New-onset left bundle branch block (LBBB) is a known complication associated with transcatheter aortic valve implantation (TAVI). 
However, the predictors of persistent LBBB after TAVI with a balloon-expandable valve (BEV) and its clinical consequences are unknown. Therefore, the 
objectives of this study were to evaluate the predictors and prognostic value of new-onset persistent LBBB in patients undergoing TAVI with a BEV.
Methods: Of 230 consecutive patients who underwent TAVI with a BEV at our institution, a total of 110 patients who had no baseline ventricular 
conduction disturbances (VCD) or previous permanent pacemaker implantation (PPI) were included in the study. Patients were on continuous ECG 
monitoring during hospitalization and 12-lead ECG was performed daily until hospital discharge. All VCD and clinical events were prospectively 
recorded. Follow-up was available in all patients at a median of 12 (25th-75th IQR: 8-24) months following TAVI. The criteria for PPI were the 
occurrence of advanced atrioventricular block or severe symptomatic bradycardia
Results: New LBBB was observed in 40.9% of the patients immediately after TAVI, and persisted at hospital discharge in 35.5% of them (17.6% of 
the study population). Baseline QRS duration (OR for each increase of 4 msec:1.57, 95% CI:1.10-2.24, p=0.012) and aortic valve calcium volume 
(OR 3.01 for each increase of 500 mm3, 95% CI:1.02-8.88, p=0.045) were independent predictors of persistent LBBB. Patients with persistent 
LBBB at hospital discharge had a higher incidence of syncope (18.8% vs. 1.3%, p=0.01) and PPI (25% vs 0%, p=0.001) during the follow-up period. 
Persistent LBBB was not associated with a higher incidence of mortality (6.3% vs. 18.3%, p=0.45), cardiac mortality (0% vs. 6.7%, p=0.582) or 
sudden death (0% vs. 1.3%, p=0.824) at follow-up.
Conclusion: Up to 41% of the patients with no prior VCD developed new LBBB following TAVI with a BEV, though it was only transient in about two 
thirds of patients. Longer QRS duration and greater valve calcification determined a higher rate of persistent LBBB. Patients with persistent LBBB at 
hospital discharge had a higher rate of PPI but not sudden death at 1-year follow-up.
